Joost H G, Hasselblatt A
Naunyn Schmiedebergs Arch Pharmacol. 1979 Apr;306(3):185-8. doi: 10.1007/BF00507101.
Glibenclamide, a "second generation" sulfonylurea, produced the same pattern of insulin release from the perfused rat pancreas as did tolbutamide. The stimulatory effect was closely dependent on the glucose concentration present. Both agents enhanced insulin secretion at 5--10 mM glucose, whereas no additional insulin was released when maximally stimulating levels of glucose (20 and 30 mM) were present. The concentrations of glibenclamide stimulating insulin release were 100--400 times lower than equieffective levels of tolbutamide. At glucose levels of 3 or 8 mM, however, glibenclamide did not liberate significantly more insulin from the pancreas than did tolbutamide. Thus the differences of tolbutamide and glibenclamide were quantitative rather than qualitative. Although the active concentrations differed the effects produced were comparable.
格列本脲,一种“第二代”磺脲类药物,从灌注的大鼠胰腺中产生的胰岛素释放模式与甲苯磺丁脲相同。刺激作用紧密依赖于当时的葡萄糖浓度。两种药物在葡萄糖浓度为5 - 10 mM时均增强胰岛素分泌,而当存在最大刺激水平的葡萄糖(20和30 mM)时,没有额外的胰岛素释放。刺激胰岛素释放的格列本脲浓度比甲苯磺丁脲的等效有效水平低100 - 400倍。然而,在葡萄糖水平为3或8 mM时,格列本脲从胰腺中释放的胰岛素并不比甲苯磺丁脲显著更多。因此,甲苯磺丁脲和格列本脲的差异是定量的而非定性的。虽然活性浓度不同,但产生的效果是相当的。